MedPath

The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction

Phase 4
Completed
Conditions
Pediatric
ED95
Sedation
General Anesthesia
Interventions
Registration Number
NCT06061159
Lead Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Brief Summary

Due to the incomplete development of systems and low pain thresholds in the pediatric population, good general anesthesia is required during the perioperative period to ensure the smooth progress of the surgery.Propofol is often used for anesthesia induction in clinical work, which can achieve good anesthesia effects. However, this drug has obvious injection pain and is prone to significant inhibition of blood circulation, and may even lead to adverse conditions such as respiratory depression in children. For the pediatric population, maintaining appropriate anesthesia depth and stable circulation during the induction period of general anesthesia has always been a focus of attention and research by anesthesiologists.Remimazolam besylate is a new type of water-soluble ultra short acting benzodiazepine drug that is hydrolyzed and metabolized by plasma esterase in the body, independent of liver and kidney function, and the metabolite zolam propionic acid has no pharmacological activity; Rapid onset and failure, short sedation recovery time; Has little impact on respiration and circulation; And there is no injection pain.Remazolam besylate is highly suitable for children due to its characteristics, and some studies have demonstrated the safety of intravenous injection of Remazolam besylate. However, there is limited research on its dosage exploration, which to some extent limits its clinical application in children.This study aims to explore the 95% effective dose (ED95) of single intravenous injection of remidazolam besylate in children of different age groups, providing a theoretical basis for the use of remidazolam besylate in pediatric anesthesia.

Detailed Description

This experiment was divided into three groups based on the age of the children, namely 1-3 years old, 4-6 years old, 7-12 years old, with an initial dose of 0.2mg/kg. The time of consciousness loss in the children was evaluated after injection of ramazolam besylate to determine whether sedation had been achieved. The next dose was adjusted to 0.05mg/kg according to biased coin design,to further explore the ED95 of a single intravenous injection of ramazolam in children of different age groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  1. with American Society of Anesthesiologists (ASA) physical status I or II;
  2. aged 1-12 years;
  3. children with weight for age within the normal range;
  4. were scheduled general anesthesia surgery
Exclusion Criteria
  1. Children who had gastrointestinal,Cardiovascular or endocrine dysfunction;
  2. contraindication to preoperative sedation or had a known allergy or hypersensitive reaction to remimazolam;
  3. recently respiratory infection, mental disorder;
  4. other reasons that researchers hold it is not appropriate to participate in this trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1-3years oldRemimazolam besylatesingle intravenous bolus remimazolam about 5min before general anesthesia induction
3-6years oldRemimazolam besylatesingle intravenous bolus remimazolam about 5min before general anesthesia induction
6-12years oldRemimazolam besylatesingle intravenous bolus remimazolam about 5min before general anesthesia induction
Primary Outcome Measures
NameTimeMethod
the time of the loss of consciousness(LOC)during anaesthetic induction

Modified Observers Assessment of Alertness/Sedation (MOAA/S) score of 1 or deeper within 1 minute, and maintained until the end of the 5-minute observation period.

Secondary Outcome Measures
NameTimeMethod
Modified observer's assessment of alertness/sedation(MOAA/S)scaleEvery 1 minutes after single intravenous bolus remimazolam

5-Subject responds readily to name spoken in a normal tone; 4 -Lethargic response of a subject to a name spoken in a normal tone; 3 -The subject responds only after a name is called loudly and repeatedly; 2 -The subject responds only after mild prodding or shaking;

1 -The subject responds only after a painful trapezius squeeze; 0 -The subject does not respond to painful trapezius squeeze. MOAA/S score ≤ 1 points represent successful sedation

BISEvery 1 minutes after single intravenous bolus remimazolam

BIS values range from 0 to 100. A value of 0 represents the absence of brain activity, and 100 represents the awake state.

BIS values between 60 to 80 represent sedation; BIS values between 40 to 60 represent adequate general anesthesia for a surgery; values less than 40 represent a deep hypnotic state.

Recovery timeWithin up to 30 minutes after child's first eye opening in the postoperative period

The time from discontinuation of sevoflurane to the first open eye of the children and to achieve the modified aldrete scole ≥9.

then the aldrete scole's minimum value is 0 and maximum value is 10, and higher scores mean a better or outcome.

The modified aldrete scole consists of five items. Each item is scored 0-2 yielding a total between 0 and 10.

Number of children with adverse effectsUp to 24 hours including preoperative, intraoperative, and postoperative periods

Number of children with adverse effects:

1、Bradycardia and/or hypotension need for hemodynamic support; 2、Desaturation is defined as Oxygen desaturation \<90%; 3、Nausea and vomiting; 4、Any adverse effects requiring interventions.

Rate of Pediatric anesthesia emergence deliriumWithin up to 15-30 minutes after child's first eye opening in the postoperative period

The pediatric anesthesia emergence delirium scale consists of five items. Each item is scored 0-4 yielding a total between 0 and 20.

The degree of emergence delirium increased directly with the total score. pediatric anesthesia emergence delirium scale ≥12 at any time indicates presence of emergence delirium.

Trial Locations

Locations (1)

The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

🇨🇳

Wenzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath